CN103458881B - Alk抑制剂的使用方法 - Google Patents
Alk抑制剂的使用方法 Download PDFInfo
- Publication number
- CN103458881B CN103458881B CN201280007465.9A CN201280007465A CN103458881B CN 103458881 B CN103458881 B CN 103458881B CN 201280007465 A CN201280007465 A CN 201280007465A CN 103458881 B CN103458881 B CN 103458881B
- Authority
- CN
- China
- Prior art keywords
- alk
- compound
- eml4
- phenyl
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438878P | 2011-02-02 | 2011-02-02 | |
| US61/438,878 | 2011-02-02 | ||
| PCT/US2012/023669 WO2012106540A1 (en) | 2011-02-02 | 2012-02-02 | Methods of using alk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103458881A CN103458881A (zh) | 2013-12-18 |
| CN103458881B true CN103458881B (zh) | 2015-08-12 |
Family
ID=45582065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280007465.9A Active CN103458881B (zh) | 2011-02-02 | 2012-02-02 | Alk抑制剂的使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8703787B2 (https=) |
| EP (1) | EP2670401B1 (https=) |
| JP (1) | JP5837095B2 (https=) |
| KR (1) | KR101521861B1 (https=) |
| CN (1) | CN103458881B (https=) |
| AU (1) | AU2012212142B2 (https=) |
| BR (1) | BR112013019643B1 (https=) |
| CA (1) | CA2824092C (https=) |
| CY (1) | CY1116662T1 (https=) |
| DK (1) | DK2670401T3 (https=) |
| EA (1) | EA023404B1 (https=) |
| ES (1) | ES2543567T3 (https=) |
| HR (1) | HRP20150946T1 (https=) |
| HU (1) | HUE025395T2 (https=) |
| ME (1) | ME02200B (https=) |
| MX (1) | MX2013008791A (https=) |
| PL (1) | PL2670401T3 (https=) |
| PT (1) | PT2670401E (https=) |
| RS (1) | RS54189B1 (https=) |
| SI (1) | SI2670401T1 (https=) |
| SM (1) | SMT201500300B (https=) |
| WO (1) | WO2012106540A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015010221B1 (pt) | 2012-11-06 | 2022-09-13 | Shanghai Fochon Pharmaceutical Co., Ltd. | Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento |
| WO2014074580A1 (en) * | 2012-11-07 | 2014-05-15 | Novartis Ag | Combination therapy |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| ITMI20131124A1 (it) | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
| SG11201600055PA (en) * | 2013-07-11 | 2016-02-26 | Betta Pharmaceuticals Co Ltd | Protein tyrosine kinase modulators and methods of use |
| JP6479812B2 (ja) * | 2013-08-28 | 2019-03-06 | ノバルティス アーゲー | 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| EP3086810A2 (en) * | 2013-12-23 | 2016-11-02 | Novartis AG | Pharmaceutical combinations |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CA2952787A1 (en) * | 2014-06-17 | 2015-12-23 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| US10259816B2 (en) | 2015-04-24 | 2019-04-16 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| CN106220608B (zh) * | 2016-07-25 | 2018-11-27 | 安润医药科技（苏州）有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| EP3504203B1 (en) * | 2016-08-29 | 2022-09-28 | The Regents of The University of Michigan | Aminopyrimidines as alk inhibitors |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101616895A (zh) * | 2006-12-08 | 2009-12-30 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| NZ585188A (en) * | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20090236334A1 (en) | 2006-07-10 | 2009-09-24 | Rf Dynamics Ltd | Food preparation |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| US8592432B2 (en) * | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
-
2012
- 2012-02-02 MX MX2013008791A patent/MX2013008791A/es unknown
- 2012-02-02 HU HUE12703670A patent/HUE025395T2/en unknown
- 2012-02-02 KR KR1020137023001A patent/KR101521861B1/ko active Active
- 2012-02-02 SI SI201230285T patent/SI2670401T1/sl unknown
- 2012-02-02 HR HRP20150946TT patent/HRP20150946T1/hr unknown
- 2012-02-02 WO PCT/US2012/023669 patent/WO2012106540A1/en not_active Ceased
- 2012-02-02 EP EP12703670.5A patent/EP2670401B1/en active Active
- 2012-02-02 ME MEP-2015-127A patent/ME02200B/me unknown
- 2012-02-02 PT PT127036705T patent/PT2670401E/pt unknown
- 2012-02-02 US US13/981,046 patent/US8703787B2/en active Active
- 2012-02-02 CN CN201280007465.9A patent/CN103458881B/zh active Active
- 2012-02-02 AU AU2012212142A patent/AU2012212142B2/en active Active
- 2012-02-02 EA EA201391114A patent/EA023404B1/ru not_active IP Right Cessation
- 2012-02-02 PL PL12703670T patent/PL2670401T3/pl unknown
- 2012-02-02 CA CA2824092A patent/CA2824092C/en active Active
- 2012-02-02 JP JP2013552637A patent/JP5837095B2/ja active Active
- 2012-02-02 BR BR112013019643-2A patent/BR112013019643B1/pt active IP Right Grant
- 2012-02-02 RS RS20150563A patent/RS54189B1/sr unknown
- 2012-02-02 DK DK12703670.5T patent/DK2670401T3/en active
- 2012-02-02 ES ES12703670.5T patent/ES2543567T3/es active Active
-
2015
- 2015-08-28 CY CY20151100758T patent/CY1116662T1/el unknown
- 2015-11-30 SM SM201500300T patent/SMT201500300B/it unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101616895A (zh) * | 2006-12-08 | 2009-12-30 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
Non-Patent Citations (4)
| Title |
|---|
| A mouse model for EML4-ALK-positive lung cancer;Manabu Soda et al.;《Proc Natl Acad Sci USA》;20081231;第105卷(第50期);19893-19897 * |
| ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time;David E. Gerber et al.;《Cancer Cell》;20101231;548-551 * |
| EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer;JussiP.Koivunen et al.;《Clin Cancer Res》;20081231;4275－4283 * |
| Identification of NVP-TAE684, a potent, selective, and efficacious inhititor of NPM-ALK;Anna V. Galkin et al.;《Proc Natl Acad Sci USA》;20070102;第104卷(第1期);270－275 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5837095B2 (ja) | 2015-12-24 |
| BR112013019643B1 (pt) | 2022-04-19 |
| CN103458881A (zh) | 2013-12-18 |
| PL2670401T3 (pl) | 2015-11-30 |
| ES2543567T3 (es) | 2015-08-20 |
| HUE025395T2 (en) | 2016-02-29 |
| CA2824092A1 (en) | 2012-08-09 |
| MX2013008791A (es) | 2013-10-07 |
| ME02200B (me) | 2016-02-20 |
| EP2670401A1 (en) | 2013-12-11 |
| SMT201500300B (it) | 2016-01-08 |
| HRP20150946T1 (hr) | 2015-10-09 |
| SI2670401T1 (sl) | 2015-10-30 |
| AU2012212142A1 (en) | 2013-08-15 |
| US20130296357A1 (en) | 2013-11-07 |
| JP2014504646A (ja) | 2014-02-24 |
| DK2670401T3 (en) | 2015-09-07 |
| EA023404B1 (ru) | 2016-05-31 |
| AU2012212142B2 (en) | 2015-09-24 |
| WO2012106540A1 (en) | 2012-08-09 |
| CA2824092C (en) | 2020-06-30 |
| EA201391114A1 (ru) | 2013-12-30 |
| CY1116662T1 (el) | 2017-03-15 |
| KR20130121174A (ko) | 2013-11-05 |
| BR112013019643A2 (pt) | 2016-10-04 |
| KR101521861B1 (ko) | 2015-05-21 |
| PT2670401E (pt) | 2015-10-12 |
| EP2670401B1 (en) | 2015-06-10 |
| RS54189B1 (sr) | 2015-12-31 |
| US8703787B2 (en) | 2014-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103458881B (zh) | Alk抑制剂的使用方法 | |
| AU2019314624B2 (en) | Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases | |
| WO2017013160A1 (en) | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers | |
| US12414945B2 (en) | Therapeutic agent for breast cancer | |
| CN114366743A (zh) | 具有驱动致癌突变的癌症的治疗 | |
| KR20190110581A (ko) | 암 치료 | |
| CN111870600B (zh) | 索拉非尼、瑞戈非尼及其类似物或衍生物的新应用 | |
| WO2021027912A1 (zh) | 一种含西达本胺的抗肿瘤药物组合物及其应用 | |
| CN113543784A (zh) | 用于治疗或预防癌症的喹啉衍生物 | |
| KR20210126654A (ko) | 암 치료 | |
| US20210179591A1 (en) | New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors | |
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| WO2025157287A1 (zh) | 包含prmt5抑制剂和egfr抑制剂的药物组合物 | |
| CN113116895A (zh) | 用于治疗神经母细胞瘤的喹啉衍生物 | |
| TW202140005A (zh) | 用於治療發炎疾病之新穎藥物 | |
| US20250339412A1 (en) | Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine | |
| WO2025174879A1 (en) | Methods of reducing or eliminating measurable residual disease | |
| CN115040519A (zh) | Egfr抑制剂用于治疗非常见或非经典突变的用途 | |
| CN117177754A (zh) | Raf抑制剂和mek抑制剂的组合 | |
| HK40007956A (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
| WO2008031357A1 (fr) | (3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one utile dans la fabrication de médicaments pour traiter les cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160106 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: British Bermuda, Hamilton Patentee before: Novartis international pharmaceuticals Ltd. Effective date of registration: 20160106 Address after: British Bermuda, Hamilton Patentee after: Novartis international pharmaceuticals Ltd. Address before: British Bermuda, Hamilton Patentee before: IRM LLC |
|
| IP01 | Partial invalidation of patent right | ||
| IP01 | Partial invalidation of patent right |
Commission number: 4W117290 Conclusion of examination: In the text modified by the patentee on February 26, 2024, maintain the validity of the invention patent right with application number 201280007465.9. Decision date of declaring invalidation: 20241010 Decision number of declaring invalidation: 569435 Denomination of invention: How to use ALK inhibitors Granted publication date: 20150812 Patentee: NOVARTIS AG |